Testosterone and other AAS, which have a schedule III classification by the Controlled Substances Act, may be abused by adults and adolescents, including athletes and body builders.
“Abuse of testosterone, usually at doses higher than those typically prescribed and usually in conjunction with other AAS, is associated with serious safety risks affecting the heart, brain, liver, mental health, and endocrine system,” the FDA notes.
Reported serious adverse outcomes include myocardial infarction, heart failure, stroke, depression, hostility, aggression, liver toxicity, and male infertility. People abusing high doses of testosterone have also reported withdrawal symptoms, such as depression, fatigue, irritability, loss of appetite, decreased libido, and insomnia, the agency says.
Source: FDA Adds New Warnings to All Testosterone Product Labels
Source: Safety Alerts for Human Medical Products > Testosterone and Other Anabolic Androgenic Steroids (AAS): FDA Statement – Risks Associated With Abuse and Dependence
It is interesting you no longer see those Low-T commercials on television any more. Really? Just another clever marketing campaign to create a disease that doesn’t exist along with a convenient drug based solution. What side effects?
Read this book. Now.
Source: Bill Moyers Journal . Profile . Melody Petersen | PBS
FDA Approves Bupropion/Naltrexone Contrave for Obesity.
If I’m understanding this correctly we now have an anti-depressant combined with a drug originally approved for treating opioid, then alcohol addiction, approved by the FDA to treat obesity.
This will be interesting.
Obesity drugs have side effects. The reason it’s taken three years for the FDA to approve NB32/Contrave is that obesity drugs have serious side effects. So serious, in fact, that several major diet drugs have been yanked from the market, making doctors, regulators and yes, investors shy away. Cardiovascular disease and mood problems are just two of the potentially serious side effects associated with Qsymia and Belviq. Older drugs Xenical and Alli carry a risk of permanent liver and kidney damage. And those weight loss supplements you buy over the counter? Some are deadly.
via Contrave: Is This The Weight Loss Drug We’ve Been Waiting For?.
Like I said, this will be interesting.
Safety Alerts for Human Medical Products > Pradaxa dabigatran: Drug Safety Communication – Lower Risk for Stroke and Death, but Higher Risk for GI Bleeding Compared to Warfarin.
ISSUE: The FDA recently completed a new study in Medicare patients comparing Pradaxa to warfarin, for risk of ischemic or clot-related stroke, bleeding in the brain, major gastrointestinal (GI) bleeding, myocardial infarction (MI), and death. The new study included information from more than 134,000 Medicare patients, 65 years or older, and found that among new users of blood-thinning drugs, Pradaxa was associated with a lower risk of clot-related strokes, bleeding in the brain, and death, than warfarin. The study also found an increased risk of major gastrointestinal bleeding with use of Pradaxa as compared to warfarin. The MI risk was similar for the two drugs.
Importantly, the new study is based on a much larger and older patient population than those used in FDA’s earlier review of post-market data, and employed a more sophisticated analytical method to capture and analyze the events of concern. This study’s findings, except with regard to MI, are consistent with the clinical trial results that provided the basis for Pradaxa’s approval. As a result of these latest findings, the FDA still considers Pradaxa to have a favorable benefit to risk profile and have made no changes to the current label or recommendations for use.
Safety Alerts for Human Medical Products > Eszopiclone Containing Sleep Aids: Drug Safety Communication – Can Cause Next-Day Impairment.
A study of Lunesta found that the previously recommended dose of 3 mg can cause impairment to driving skills, memory, and coordination that can last more than 11 hours after receiving an evening dose (see Data Summary). Despite these driving and other problems, patients were often unaware they were impaired. The new lower recommended starting dose of 1 mg at bedtime will result in less drug in the blood the next day.
Safety Information > February 2014.
Get to Know an Enzyme: CYP3A4.
I routinely check the FDA drug safety information for personal reasons. One thing led to another, thus the reason for the CYP3A4 link. If you like puzzles, try to figure out why I’m reading up on CYP3A4. My son the molecular biochemist soon to be MD would have no problem figuring this out.
Safety Information > December 2013.
Memory permitting I will link to this FDA webpage on a regular basis. From my perspective the adverse reactions are the most interesting nuggets of information.